QRxPharma tumbles on 2nd FDA rejection for pain drug MoxDuo
This article was originally published in Scrip
Executive Summary
Shares of QRxPharma tumbled about 13.3% on 28 August in the US over-the-counter markets after the company revealed it had received a second complete response letter (CRL) from the US FDA for the firm's new drug application (NDA) for MoxDuo as a treatment for moderate-to-severe acute pain.